A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
about
Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinomaManagement of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapyγ-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF-κB-regulated anti-apoptotic gene products.End points for new agents in induction chemotherapy for locally advanced head and neck cancers.Docetaxel-loaded pluronic p123 polymeric micelles: in vitro and in vivo evaluation.Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neckPopulation pharmacokinetics of weekly docetaxel in patients with advanced cancer.Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.Taxanes in head and neck cancer.Induction chemotherapy in the management of squamous cell carcinoma of the head and neck.Systemic therapy in head and neck cancer: changing paradigm.Combined modality treatment of laryngeal squamous cell carcinoma.Docetaxel in the management of patients with head and neck squamous cell carcinoma.Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancerPhase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck.Current treatment options for metastatic head and neck cancer.Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines.A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin.
P2860
Q33436548-8F66EC4C-2F1B-4BDA-AD79-05D1FB48C5A8Q33751186-05678CC8-69DD-4964-9811-45F510FA1E85Q33885578-3CBD550C-CAD1-46C2-A0D3-865C6DB01018Q34471481-D107B453-B912-4C3F-A04D-EC0A40971024Q34784828-0010606B-594F-4314-B971-1286AA3FB5CBQ35036060-028F757A-2C22-4D33-AC55-82E72F19B7CFQ35056376-CCC06E46-0604-4FED-A831-7F18CAD6F3E1Q35825890-90FEB8BB-E0CB-4BE5-A08C-6BBF9CAEC98DQ35986419-8B40FB83-1A6F-4BDF-873B-2F8ECC742DB5Q36429649-20FABDB5-C075-450A-BA1A-990EED2822A6Q36613979-57627CF7-BA9F-4CE1-9809-99263F3557A6Q36627358-0825073C-0A01-4676-9B96-B2499A9A12CCQ36752037-3D73D32D-5BDC-4F17-B9A7-6C5FC07C493EQ37202758-EDBF1D98-051D-4D20-BD38-79CDA9C376EFQ37232854-E9A15E93-CC34-41F6-A59C-33E8CCABCA6DQ37310298-39B41919-E28C-4960-8F2E-AF7D7AF3BB31Q37870929-86E37ACC-94D2-47A3-8211-856A8C7AB821Q37976623-65518920-9AB7-4CC6-9654-A4DE851496F4Q39516103-F5FC9C15-64DE-4C16-AE66-3A2E481659E9Q42999498-A90CFF67-25E4-44AF-847D-0C2671C48742Q43906898-3D6619CF-3CA4-4B30-96ED-527BE6CB2ED1Q53134485-E824F58D-5A4E-4975-A71A-B99698A8D6AF
P2860
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
A phase II study of docetaxel ...... arcinoma of the head and neck.
@ast
A phase II study of docetaxel ...... arcinoma of the head and neck.
@en
type
label
A phase II study of docetaxel ...... arcinoma of the head and neck.
@ast
A phase II study of docetaxel ...... arcinoma of the head and neck.
@en
prefLabel
A phase II study of docetaxel ...... arcinoma of the head and neck.
@ast
A phase II study of docetaxel ...... arcinoma of the head and neck.
@en
P2093
P2860
P921
P356
P1476
A phase II study of docetaxel ...... arcinoma of the head and neck.
@en
P2093
D Oulid-Aissa
J P Armand
M De Forni
S Bordessoule
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690715
P407
P577
1999-10-01T00:00:00Z
P5875
P6179
1021781121